AFX 9901Alternative Names: AFX-9901
Latest Information Update: 24 Jun 2008
At a glance
- Originator Afecta Pharmaceuticals
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Clinical Phase Unknown Cancer
Most Recent Events
- 24 Jun 2008 Investigation in Cancer in USA (unspecified route)